MiMedx Reports Mixed Q2 2026 Results Amid Sanara MedTech Acquisition
Event summary
- MiMedx reported Q2 2026 net sales of $64M, down 35% YoY due to a 61% decline in Wound sales.
- Surgical product sales grew 15% YoY, led by AMNIOFIX® and AMNIOEFFECT®.
- MiMedx announced plans to acquire Sanara MedTech for $350M in cash and stock.
- The company expects to return to profitability in the second half of 2026.
The big picture
MiMedx's Q2 results reflect ongoing challenges in the wound care sector due to Medicare reimbursement changes, while its Surgical franchise shows resilience. The acquisition of Sanara MedTech positions MiMedx to expand its product portfolio and market reach, though integration risks and reimbursement headwinds remain key strategic concerns.
What we're watching
- Reimbursement Impact
- How Medicare reimbursement changes will continue to affect Wound business volumes and pricing.
- Acquisition Integration
- The pace at which MiMedx can integrate Sanara MedTech and realize expected synergies.
- Profitability Path
- Whether cost reduction measures will be sufficient to achieve breakeven Adjusted EBITDA for the full year 2026.
Related topics